The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines

Samia Mora, Kiran Musunuru, Roger S. Blumenthal

Research output: Contribution to journalShort surveypeer-review

Abstract

JUPITER has demonstrated that combining hsCRP testing with traditional testing of lipids can reduce incident CVD in high-risk asymptomatic individuals by 44% and all-cause mortality by approximately 20%, extending the therapeutic use of statins for the primary prevention of CVD. Guidelines for practitioners could include testing asymptomatic individuals for increased concentrations of hsCRP in men ≥50 years and women ≥60 years when LDL-C concentrations are not increased and for whom the decision to treat with statin therapy is not otherwise clear.

Original languageEnglish (US)
Pages (from-to)219-228
Number of pages10
JournalClinical chemistry
Volume55
Issue number2
DOIs
StatePublished - Feb 1 2009

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Fingerprint

Dive into the research topics of 'The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines'. Together they form a unique fingerprint.

Cite this